臨床検査52巻13号

2008年12月発行

今月の主題 凝固制御 抗凝固薬の新展開

外因系凝固阻害薬

著者： 鈴木宏治¹

所属機関： ¹三重大学大学院医学系研究科分子病態学

ページ範囲：P.1587 - P.1591

　外因系凝固阻害物質である組織因子経路インヒビター(TFPI)の組換え蛋白質tifacoginは，組織因子と複合体を形成する第Ⅶa因子および第Ⅹa因子を阻害する．播種性血管内凝固症候群(DIC)の治療薬として期待されたtifacoginについて，重症の敗血症患者を対象とした臨床試験が行われた．しかし，第Ⅲ相試験でその有効性がみられなかったため，本適応での開発は中止された．

参考文献

1) Mackman N, Tilley RE, Key NS：Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Bio　l27：1687-1693, 2007

2) Riewald M, Ruf W：Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci USA　98：7742-7747, 2001

3) Hjortoe GM, Petersen LC, Albrektsen T, et al：Tissue factor-factor Ⅶa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood　103：3029-3037, 2004

4) Broze GJ Jr：Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med　46：103-112, 1995

5) 御舘靖雄，朝倉英策：組織因子経路インヒビター(TFPI)．血栓と循環　12：197-200，2004

6) 加藤久雄，亀井加恵子：立体構造からみたTFPI(Tissue Factor Pathway Inhibitor)の作用機構．日本血栓止血学会誌　10：299-304，1999

7) Huang ZF, Higuchi D, Lasky N, et al：Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood　90：944-951, 1997

8) Dahm A, Van Hylckama Vlieg A, Bendz B, et al：Low levels of tissue factor pathway inhibitor(TFPI)increase the risk of venous thrombosis. Blood　101：4387-4392, 2003

9) Hackeng TM, Seré KM, Tans G, et al：Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA　103：3106-3111, 2006

10) Jang Y, Guzman LA, Lincoff AM, et al：Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation　92：3041-3050, 1995

11) Oltrona L, Speidel CM, Recchia D, et al：Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation　96：646-652, 1997

12) Kamikubo Y, Nakahara Y, Takemoto S, et al：Human recombinant tissue-factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells. FEBS Lett　407：116-120, 1997

13) Horie S, Hiraishi S, Hamuro T, et al：Oxidized low-density lipoprotein associates strongly with carboxy-terminal domain of tissue factor pathway inhibitor and reduces the catalytic activity of the protein. Thromb Haemost　87：80-85, 2002

14) Hoppensteadt D, Callas D, Iqbal O, et al：Fibrinolytic and hemodynamic compromise by adjunct therapeutic agents used in thrombolysis. Comparative studies with recombinant tissue factor pathway inhibitor. Fibrinolysis　8：75, 1994

15) Abendschein DR, Meng YY, Torr-Brown S, et al：Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. Circulation　92：944-949, 1995

16) Kaiser B, Fareed J：Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis. Thromb Haemost　76：615-620, 1996

17) Lefkovits J, Malycky JL, Rao JS, et al：Selective inhibition of factor Ⅹa is more efficient than factor Ⅶa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model. J Am Coll Cardiol　28：1858-1865, 1996

18) Enkhbaatar P, Okajima K, Uchiba M, et al：Recombinant tissue factor pathway inhibitor prevents lipopolysaccharide-induced systemic hypotension in rats by inhibiting excessive production of nitric oxide. Thromb Haemost　86：1573-1577, 2001

19) Yin X, Yutani C, Ikeda Y, et al：Tissue factor pathway inhibitor gene delivery using HVJ-AVE liposomes markedly reduces restenosis in atherosclerotic arteries. Cardiovasc Res　56：454-463, 2002

20) Abraham E, Reinhart K, Svoboda P, et al：Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis：a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med　29：2081-2089, 2001

21) Abraham E, Reinhart K, Opal S, et al：Efficacy and safety of tifacogin(recombinant tissue factor pathway inhibitor)in severe sepsis：a randomized controlled trial. JAMA　290：238-247, 2003